Supplementary Table S2. Data of MPP or MPC patients who were treated with EGFR TKIs after disease recurrence.

No. / Age (y) / Sex / Smoking History / Stage / Predominant
Histology / Mutation / EGFR TKIs / Response
1 / 72 / F / Never / IIIa / MPP / E19 del / Gefitinib / CR
2 / 60 / F / Never / Ib / MPCACI / E19 del / Erlotinib / PR
3 / 66 / F / Never / IIIa / MPP / L858R / Gefitinib / PR
4 / 69 / F / Never / IIb / MPCACI / L858R / Gefitinib / PR
5 / 63 / M / Ever / IIb / MPCACI / L858R / Gefitinib / PR
6 / 67 / F / Never / Ib / MPCPAP / E19 del / Gefitinib / PR
7 / 69 / F / Never / Ib / MPCACI / E19 del / Gefitinib / PR
8 / 60 / F / Never / IIIa / MPCPAP / E19 del / Gefitinib / PR
9 / 63 / F / Never / IIIa / MPCACI / E19 del / Gefitinib / SD
10 / 77 / M / Ever / Ia / MPP / L858R / Gefitinib / PR
11 / 69 / F / Never / IIa / MPCACI / L858R / Gefitinib / SD
12 / 64 / M / Ever / IIIa / MPP / L858R / Erlotinib / SD
13 / 66 / F / Never / IIIa / MPCPAP / L858R / Gefitinib / PR
14 / 80 / F / Never / IIIa / MPCACI / L858R / Gefitinib / PR
15 / 54 / M / Ever / IIIa / MPCACI / L858R / Gefitinib / SD
16 / 76 / M / Never / IIIa / MPCACI / E19 del / Gefitinib / PR
17 / 51 / M / Never / Ib / MPP / E19 del / Gefitinib / SD
18 / 58 / M / Never / IIIa / MPCPAP / E19 del / Erlotinib / PR
Abbreviations: F, female; M, male; MPP, micropapillary predominant lung adenocarcinoma; MPC, non-micropapillary predominant lung adenocarcinoma with a micropapillary component ≥ 5%; ACI, acinar predominant lung adenocarcinoma; PAP, papillary predominant lung adenocarcinoma; E19 del, exon 19 deletions; TKIs, tyrosine kinase inhibitors; CR, complete response; PR, partial response; SD, stable disease.

1